• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Zura Bio Limited

    5/2/24 4:16:04 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ZURA alert in real time by email
    SC 13G 1 tm2413333d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Zura Bio Limited

    (Name of Issuer)

     

    Class A Ordinary Shares, par value $0.0001 per share

    (Title of Class of Securities)

     

    G9TY5A101

    (CUSIP Number)

     

    April 22, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨  Rule 13d-1(b)
    x  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. G9TY5A101 Page 2 of 17

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

     

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    6,399,619 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    6,399,619 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,399,619 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
      
    (2)Consists of (i) 1,312,448 Class A ordinary shares and 440,429 Class A ordinary shares underlying pre-funded warrants (“PFWs”), of which, 82,029 are currently exercisable held by Venrock Healthcare Capital Partners III, L.P.; (ii) 131,305 Class A ordinary shares and 44,063 Class A ordinary shares underlying PFWs, of which, 8,207 are currently exercisable held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,579,413 Class A ordinary shares and 1,536,750 Class A ordinary shares underlying PFWs, of which, 286,217 are currently exercisable held by Venrock Healthcare Capital Partners EG, L.P. Under the terms of the PFWs, the Issuer may not effect the exercise of any such PFWs, and a holder will not be entitled to exercise any portion of such PFWs, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.
      
    (3)This percentage is calculated based upon the sum of (i) 43,593,678 Class A ordinary shares outstanding as of April 18, 2024, as reported in the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission (the “SEC”) on April 23, 2024; (ii) 20,090,128 Class A ordinary shares issued in the private placement of equity securities by the Issuer that closed on April 18, 2024 (the “Private Placement”); and (iii) 376,453 Class A ordinary shares issuable upon the exercise of the PFWs described in Footnote 2 above.

     

     

     

     

    CUSIP No. G9TY5A101 Page 3 of 17

     

    1.

    Names of Reporting Persons

     

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

     

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    6,399,619 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    6,399,619 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,399,619 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
      
    (2)Consists of (i) 1,312,448 Class A ordinary shares and 440,429 Class A ordinary shares underlying PFWs, of which, 82,029 are currently exercisable held by Venrock Healthcare Capital Partners III, L.P.; (ii) 131,305 Class A ordinary shares and 44,063 Class A ordinary shares underlying PFWs, of which, 8,207 are currently exercisable held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,579,413 Class A ordinary shares and 1,536,750 Class A ordinary shares underlying PFWs, of which, 286,217 are currently exercisable held by Venrock Healthcare Capital Partners EG, L.P. Under the terms of the PFWs, the Issuer may not effect the exercise of any such PFWs, and a holder will not be entitled to exercise any portion of such PFWs, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.
      
    (3)This percentage is calculated based upon the sum of (i) 43,593,678 Class A ordinary shares outstanding as of April 18, 2024, as reported in the Issuer’s Current Report on Form 8-K, filed with the SEC on April 23, 2024; (ii) 20,090,128 Class A ordinary shares issued in the Private Placement; and (iii) 376,453 Class A ordinary shares issuable upon the exercise of the PFWs described in Footnote 2 above.

     

     

     

     

    CUSIP No. G9TY5A101 Page 4 of 17

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

     

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    6,399,619 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    6,399,619 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,399,619 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
      
    (2)Consists of (i) 1,312,448 Class A ordinary shares and 440,429 Class A ordinary shares underlying PFWs, of which, 82,029 are currently exercisable held by Venrock Healthcare Capital Partners III, L.P.; (ii) 131,305 Class A ordinary shares and 44,063 Class A ordinary shares underlying PFWs, of which, 8,207 are currently exercisable held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,579,413 Class A ordinary shares and 1,536,750 Class A ordinary shares underlying PFWs, of which, 286,217 are currently exercisable held by Venrock Healthcare Capital Partners EG, L.P. Under the terms of the PFWs, the Issuer may not effect the exercise of any such PFWs, and a holder will not be entitled to exercise any portion of such PFWs, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.
      
    (3)This percentage is calculated based upon the sum of (i) 43,593,678 Class A ordinary shares outstanding as of April 18, 2024, as reported in the Issuer’s Current Report on Form 8-K, filed with the SEC on April 23, 2024; (ii) 20,090,128 Class A ordinary shares issued in the Private Placement; and (iii) 376,453 Class A ordinary shares issuable upon the exercise of the PFWs described in Footnote 2 above.

     

     

     

     

    CUSIP No. G9TY5A101 Page 5 of 17

     

    1.

    Names of Reporting Persons

     

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

     

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    6,399,619 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    6,399,619 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,399,619 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
      
    (2)Consists of (i) 1,312,448 Class A ordinary shares and 440,429 Class A ordinary shares underlying PFWs, of which, 82,029 are currently exercisable held by Venrock Healthcare Capital Partners III, L.P.; (ii) 131,305 Class A ordinary shares and 44,063 Class A ordinary shares underlying PFWs, of which, 8,207 are currently exercisable held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,579,413 Class A ordinary shares and 1,536,750 Class A ordinary shares underlying PFWs, of which, 286,217 are currently exercisable held by Venrock Healthcare Capital Partners EG, L.P. Under the terms of the PFWs, the Issuer may not effect the exercise of any such PFWs, and a holder will not be entitled to exercise any portion of such PFWs, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.
      
    (3)This percentage is calculated based upon the sum of (i) 43,593,678 Class A ordinary shares outstanding as of April 18, 2024, as reported in the Issuer’s Current Report on Form 8-K, filed with the SEC on April 23, 2024; (ii) 20,090,128 Class A ordinary shares issued in the Private Placement; and (iii) 376,453 Class A ordinary shares issuable upon the exercise of the PFWs described in Footnote 2 above.

     

     

     

     

    CUSIP No. G9TY5A101 Page 6 of 17

     

    1.

    Names of Reporting Persons

     

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

     

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    6,399,619 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    6,399,619 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,399,619 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
      
    (2)Consists of (i) 1,312,448 Class A ordinary shares and 440,429 Class A ordinary shares underlying PFWs, of which, 82,029 are currently exercisable held by Venrock Healthcare Capital Partners III, L.P.; (ii) 131,305 Class A ordinary shares and 44,063 Class A ordinary shares underlying PFWs, of which, 8,207 are currently exercisable held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,579,413 Class A ordinary shares and 1,536,750 Class A ordinary shares underlying PFWs, of which, 286,217 are currently exercisable held by Venrock Healthcare Capital Partners EG, L.P. Under the terms of the PFWs, the Issuer may not effect the exercise of any such PFWs, and a holder will not be entitled to exercise any portion of such PFWs, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.
      
    (3)This percentage is calculated based upon the sum of (i) 43,593,678 Class A ordinary shares outstanding as of April 18, 2024, as reported in the Issuer’s Current Report on Form 8-K, filed with the SEC on April 23, 2024; (ii) 20,090,128 Class A ordinary shares issued in the Private Placement; and (iii) 376,453 Class A ordinary shares issuable upon the exercise of the PFWs described in Footnote 2 above.

     

     

     

     

    CUSIP No. G9TY5A101 Page 7 of 17

     

    1.

    Names of Reporting Persons

     

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

     

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    6,399,619 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    6,399,619 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,399,619 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
      
    (2)Consists of (i) 1,312,448 Class A ordinary shares and 440,429 Class A ordinary shares underlying PFWs, of which, 82,029 are currently exercisable held by Venrock Healthcare Capital Partners III, L.P.; (ii) 131,305 Class A ordinary shares and 44,063 Class A ordinary shares underlying PFWs, of which, 8,207 are currently exercisable held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,579,413 Class A ordinary shares and 1,536,750 Class A ordinary shares underlying PFWs, of which, 286,217 are currently exercisable held by Venrock Healthcare Capital Partners EG, L.P. Under the terms of the PFWs, the Issuer may not effect the exercise of any such PFWs, and a holder will not be entitled to exercise any portion of such PFWs, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.
      
    (3)This percentage is calculated based upon the sum of (i) 43,593,678 Class A ordinary shares outstanding as of April 18, 2024, as reported in the Issuer’s Current Report on Form 8-K, filed with the SEC on April 23, 2024; (ii) 20,090,128 Class A ordinary shares issued in the Private Placement; and (iii) 376,453 Class A ordinary shares issuable upon the exercise of the PFWs described in Footnote 2 above.

     

     

     

     

    CUSIP No. G9TY5A101 Page 8 of 17

     

    1.

    Names of Reporting Persons

     

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

     

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    6,399,619 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    6,399,619 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,399,619 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
      
    (2)Consists of (i) 1,312,448 Class A ordinary shares and 440,429 Class A ordinary shares underlying PFWs, of which, 82,029 are currently exercisable held by Venrock Healthcare Capital Partners III, L.P.; (ii) 131,305 Class A ordinary shares and 44,063 Class A ordinary shares underlying PFWs, of which, 8,207 are currently exercisable held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,579,413 Class A ordinary shares and 1,536,750 Class A ordinary shares underlying PFWs, of which, 286,217 are currently exercisable held by Venrock Healthcare Capital Partners EG, L.P. Under the terms of the PFWs, the Issuer may not effect the exercise of any such PFWs, and a holder will not be entitled to exercise any portion of such PFWs, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.
      
    (3)This percentage is calculated based upon the sum of (i) 43,593,678 Class A ordinary shares outstanding as of April 18, 2024, as reported in the Issuer’s Current Report on Form 8-K, filed with the SEC on April 23, 2024; (ii) 20,090,128 Class A ordinary shares issued in the Private Placement; and (iii) 376,453 Class A ordinary shares issuable upon the exercise of the PFWs described in Footnote 2 above.

     

     

     

     

    CUSIP No. G9TY5A101 Page 9 of 17

     

    Item 1.
      (a)

    Name of Issuer

    Zura Bio Limited

     
      (b)

    Address of Issuer’s Principal Executive Offices

    1489 W. Warm Springs Rd. #110
    Henderson, NV 89014

     
    Item 2.
      (a)

    Name of Person Filing

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

         
      (b) Address of Principal Business Office or, if none, Residence

     

      New York Office: Palo Alto Office:
         
      7 Bryant Park 3340 Hillview Avenue
      23rd Floor Palo Alto, CA 94304
      New York, NY 10018  

     

      (c)

    Citizenship

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     
      (d)

    Title of Class of Securities

    Class A Ordinary Shares, par value $0.0001 per share

     
      (e)

    CUSIP Number

    G9TY5A101

     
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      Not applicable

     

     

     

     

    CUSIP No. G9TY5A101 Page 10 of 17

     

    Item 4. Ownership
      (a) Amount beneficially owned:

     

      Venrock Healthcare Capital Partners III, L.P.   6,399,619(1)
      VHCP Co-Investment Holdings III, LLC   6,399,619(1)
      Venrock Healthcare Capital Partners EG, L.P.   6,399,619(1)
      VHCP Management III, LLC   6,399,619(1)
      VHCP Management EG, LLC   6,399,619(1)
      Nimish Shah   6,399,619(1)
      Bong Koh   6,399,619(1)

     

      (b) Percent of class:

     

      Venrock Healthcare Capital Partners III, L.P.   9.99%(2)
      VHCP Co-Investment Holdings III, LLC   9.99%(2)
      Venrock Healthcare Capital Partners EG, L.P.   9.99%(2)
      VHCP Management III, LLC   9.99%(2)
      VHCP Management EG, LLC   9.99%(2)
      Nimish Shah   9.99%(2)
      Bong Koh   9.99%(2)

     

      (c) Number of shares as to which the person has:
        (i) Sole power to vote or to direct the vote:

     

      Venrock Healthcare Capital Partners III, L.P.   0 
      VHCP Co-Investment Holdings III, LLC   0 
      Venrock Healthcare Capital Partners EG, L.P.   0 
      VHCP Management III, LLC   0 
      VHCP Management EG, LLC   0 
      Nimish Shah   0 
      Bong Koh   0 

     

        (ii) Shared power to vote or to direct the vote:

     

      Venrock Healthcare Capital Partners III, L.P.   6,399,619(1)
      VHCP Co-Investment Holdings III, LLC   6,399,619(1)
      Venrock Healthcare Capital Partners EG, L.P.   6,399,619(1)
      VHCP Management III, LLC   6,399,619(1)
      VHCP Management EG, LLC   6,399,619(1)
      Nimish Shah   6,399,619(1)
      Bong Koh   6,399,619(1)

     

     

     

     

    CUSIP No. G9TY5A101 Page 11 of 17

     

        (iii) Sole power to dispose or to direct the disposition of:

     

      Venrock Healthcare Capital Partners III, L.P.   0 
      VHCP Co-Investment Holdings III, LLC   0 
      Venrock Healthcare Capital Partners EG, L.P.   0 
      VHCP Management III, LLC   0 
      VHCP Management EG, LLC   0 
      Nimish Shah   0 
      Bong Koh   0 

     

        (iv) Shared power to dispose or to direct the disposition of:

     

      Venrock Healthcare Capital Partners III, L.P.   6,399,619(1)
      VHCP Co-Investment Holdings III, LLC   6,399,619(1)
      Venrock Healthcare Capital Partners EG, L.P.   6,399,619(1)
      VHCP Management III, LLC   6,399,619(1)
      VHCP Management EG, LLC   6,399,619(1)
      Nimish Shah   6,399,619(1)
      Bong Koh   6,399,619(1)

     

     

    (1)Consists of (i) 1,312,448 Class A ordinary shares and 440,429 Class A ordinary shares underlying PFWs, of which, 82,029 are currently exercisable held by Venrock Healthcare Capital Partners III, L.P.; (ii) 131,305 Class A ordinary shares and 44,063 Class A ordinary shares underlying PFWs, of which, 8,207 are currently exercisable held by VHCP Co-Investment Holdings III, LLC; and (iii) 4,579,413 Class A ordinary shares and 1,536,750 Class A ordinary shares underlying PFWs, of which, 286,217 are currently exercisable held by Venrock Healthcare Capital Partners EG, L.P. Under the terms of the PFWs, the Issuer may not effect the exercise of any such PFWs, and a holder will not be entitled to exercise any portion of such PFWs, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.
       
      VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.
       
    (2)This percentage is calculated based upon the sum of (i) 43,593,678 Class A ordinary shares outstanding as of April 18, 2024, as reported in the Issuer’s Current Report on Form 8-K, filed with the SEC on April 23, 2024; (ii) 20,090,128 Class A ordinary shares issued in the Private Placement; and (iii) 376,453 Class A ordinary shares issuable upon the exercise of the PFWs described in Footnote 1 above.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ☐

     

     1

     

     

    CUSIP No. G9TY5A101 Page 12 of 17

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable
     
    Item 8. Identification and Classification of Members of the Group
       
      Not applicable
     
    Item 9. Notice of Dissolution of Group
       
      Not applicable
     
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     2

     

     

    CUSIP No. G9TY5A101 Page 13 of 17

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: May 2, 2024

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
         
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Co-Investment Holdings III, LLC    
         
    By: VHCP Management III, LLC    
    Its: Manager    
         
    By: /s/ Sherman G. Souther    
      Name: Sherman G. Souther    
      Its: Authorized Signatory    
         
    VHCP Management III, LLC   VHCP Management EG, LLC
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    Nimish Shah    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    
         
    Bong Koh    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    

     

     

     

     

    CUSIP No. G9TY5A101 Page 14 of 17

     

    EXHIBITS

     

    A:Joint Filing Agreement

     

    B:Power of Attorney for Nimish Shah

     

    C:Power of Attorney for Bong Koh

     

     

     

     

    CUSIP No. G9TY5A101 Page 15 of 17

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Class A Ordinary Shares of Zura Bio Limited and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

     

    In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 2nd day of May, 2024.

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
         
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Co-Investment Holdings III, LLC    
         
    By: VHCP Management III, LLC    
    Its: Manager    
         
    By: /s/ Sherman G. Souther    
      Name: Sherman G. Souther    
      Its: Authorized Signatory    
         
    VHCP Management III, LLC   VHCP Management EG, LLC
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    Nimish Shah    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    
         
    Bong Koh    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    

     

     

     

     

    CUSIP No. G9TY5A101 Page 16 of 17

     

    EXHIBIT B

     

    POWER OF ATTORNEY FOR NIMISH SHAH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

    (i)prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

    (ii)take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 2nd day of May, 2024.

     

    /s/ Nimish Shah  

     

     

     

     

    CUSIP No. G9TY5A101 Page 17 of 17

     

    EXHIBIT C

     

    POWER OF ATTORNEY FOR BONG KOH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

    (i)prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

    (ii)take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 2nd day of May, 2024.

     

    /s/ Bong Koh  

     

     

     

    Get the next $ZURA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZURA

    DatePrice TargetRatingAnalyst
    11/4/2024$15.00Outperform
    Leerink Partners
    9/5/2024$5.00Neutral
    H.C. Wainwright
    5/3/2024$26.00Overweight
    Piper Sandler
    10/10/2023$10.00Buy
    Ladenburg Thalmann
    8/25/2023$17.00Outperform
    Oppenheimer
    6/22/2023$20.00Buy
    Guggenheim
    6/14/2023$14.00Buy
    Chardan Capital Markets
    5/24/2023$20.00Strong Buy
    Raymond James
    More analyst ratings

    $ZURA
    Financials

    Live finance-specific insights

    See more
    • Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

      Achieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipeline Initiated the Phase 2 TibuSURE trial in adults with systemic sclerosis (SSc) Completed a $112.5 million private placement financing in April 2024, contributing to a total of $176.5 million in cash and cash equivalents, as of December 31, 2024 Cash runway anticipated through 2027, supporting operations and funding anticipated tibulizumab data readouts in SSc and hidradenitis suppurativa (HS) Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for

      3/25/25 6:30:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

      Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025 Cash, cash equivalents and investments totaling $188.2 million as of September 30, 2024, are anticipated to support operations, as currently planned, through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter of 2024 and recent corporate updates. "In the third quarter of 2024, we made significant progress toward initiating our first Phase 2 tria

      11/7/24 6:30:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

      Initiating Phase 2 clinical trials in 2024 to evaluate ZB-106 (tibulizumab) in systemic sclerosis and hidradenitis suppurativa, and ZB-168 in alopecia areata Experienced team building the next Immunology leader Cash position of $103.9 million in cash, cash equivalents and investments is expected to support development and operations into 2026 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio") a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights. "In the third quarter, Zura Bio made significant progress

      11/13/23 6:30:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ZURA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

      TibuSHIELD has launched with the activation of its first clinical site This study is the first to evaluate dual inhibition of B-cell activating factor (BAFF) and interleukin-17A (IL-17A) pathways in adults with moderate to severe hidradenitis suppurativa (HS) TibuSHIELD will assess tibulizumab over a 28-week study period, comprising a 16-week primary efficacy assessment and a 12-week safety follow-up, conducted at clinical sites across the United States, Canada, and Europe, with an optional open-label extension (OLE) Topline results for the primary efficacy endpoint at Week 16, along with key secondary and exploratory outcomes, are anticipated in the third quarter of 2026 Zura Bio

      5/20/25 6:30:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

      Advanced the Phase 2 TibuSURE clinical trial evaluating tibulizumab in adults with systemic sclerosis (SSc) Continued preparations for the planned Phase 2 trial evaluating tibulizumab in adults with hidradenitis suppurativa (HS), expected to initiate in Q2 2025 Strengthened the team with a strategic appointment to support clinical execution and organizational growth $170.6 million in cash and cash equivalents with cash runway anticipated through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today reported financial resul

      5/8/25 6:30:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

      Achieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipeline Initiated the Phase 2 TibuSURE trial in adults with systemic sclerosis (SSc) Completed a $112.5 million private placement financing in April 2024, contributing to a total of $176.5 million in cash and cash equivalents, as of December 31, 2024 Cash runway anticipated through 2027, supporting operations and funding anticipated tibulizumab data readouts in SSc and hidradenitis suppurativa (HS) Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for

      3/25/25 6:30:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ZURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Badial Verender S.

      4 - Zura Bio Ltd (0001855644) (Issuer)

      5/12/25 4:15:32 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Technology Officer Whale Gary

      4 - Zura Bio Ltd (0001855644) (Issuer)

      3/3/25 5:03:45 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Officer Nistala Kiran

      4 - Zura Bio Ltd (0001855644) (Issuer)

      3/3/25 5:02:54 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ZURA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ploos Van Amstel Arnout bought $496,000 worth of Class A ordinary shares (80,000 units at $6.20), increasing direct ownership by 400% to 100,000 units (SEC Form 4)

      4 - Zura Bio Ltd (0001855644) (Issuer)

      5/23/24 8:53:36 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Howell Michael bought $24,999 worth of Class A ordinary shares (7,987 units at $3.13) (SEC Form 4)

      4 - Zura Bio Ltd (0001855644) (Issuer)

      4/24/24 6:54:25 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Nistala Kiran bought $10,000 worth of Class A ordinary shares (3,195 units at $3.13) (SEC Form 4)

      4 - Zura Bio Ltd (0001855644) (Issuer)

      4/24/24 6:53:25 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ZURA
    SEC Filings

    See more
    • Zura Bio Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Zura Bio Ltd (0001855644) (Filer)

      5/20/25 6:35:21 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Zura Bio Limited

      SCHEDULE 13G/A - Zura Bio Ltd (0001855644) (Subject)

      5/15/25 5:43:13 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Zura Bio Limited

      SCHEDULE 13G - Zura Bio Ltd (0001855644) (Subject)

      5/14/25 4:11:09 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ZURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ZURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

      SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

      11/14/24 5:52:59 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

      SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

      11/14/24 5:06:21 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Zura Bio Limited

      SC 13G - Zura Bio Ltd (0001855644) (Subject)

      11/14/24 4:47:14 PM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Leerink Partners initiated coverage on Zura Bio Limited with a new price target

      Leerink Partners initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00

      11/4/24 7:45:03 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Zura Bio Limited with a new price target

      H.C. Wainwright initiated coverage of Zura Bio Limited with a rating of Neutral and set a new price target of $5.00

      9/5/24 8:35:06 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Zura Bio Limited with a new price target

      Piper Sandler initiated coverage of Zura Bio Limited with a rating of Overweight and set a new price target of $26.00

      5/3/24 7:45:08 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ZURA
    Leadership Updates

    Live Leadership Updates

    See more
    • Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

      Presented data for tibulizumab at EULAR 2024, highlighting the potential relevance of dual-inhibition of both IL-17A and BAFF in autoimmune and inflammatory diseases Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in 4Q 2024 and hidradenitis suppurativa (HS) in 2Q 2025 Strengthened management and advisory team with appointment of Robert Lisicki as CEO & formation of Scientific Advisory Board Cash, cash equivalents and investments of $188.4 million as of June 30, 2024, including $112.5 million from private placement executed in April 2024, anticipated to support operations as currently planned through 2027 Zura Bio Limited

      8/13/24 9:21:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

      Significant 2023 milestones highlighted by successful Nasdaq listing, leadership team buildout, formation of strategic development and scientific plan On track to initiate Phase 2 study evaluating tibulizumab (ZB-106) for the treatment of systemic sclerosis (SSc) in 2H 2024 Appointment of CEO, Robert Lisicki, underscores Zura Bio's commitment to building leading immunology company as we prioritize excellence in strategic development and scientific planning Outgoing Founder and CEO, Someit Sidhu, M.D., will continue as a Board Director to leverage institutional knowledge and provide continued support Cash position as of December 31, 2023 totaling $99.8 million in cash, cash equi

      3/28/24 6:00:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO

      Accomplished biopharmaceutical executives bring invaluable expertise and experience to Zura Bio's Clinical Development programs Executive Leadership hires position Zura Bio for Phase 2 clinical trial readiness across multiple indications in 2024 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the appointments of Robert Lisicki as President and Chief Operating Officer, and Kiran Nistala, MBBS, PhD, as Executive Vice President Development and Chief Medical Officer, to the Executive Leadership Team. Mr. Lisicki will be responsible for developing an

      1/8/24 6:00:00 AM ET
      $ZURA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care